conclusion looking fine? pookie?
In conclusion, CRISPR-Cas9 technology can be used to increase foetal haemoglobin (HbF), by altering the BCL11A gene in beta-thalassemia. This directly addresses the question: How does CRISPR-Cas9 editing of the gene BCL11A influence the clinical nature of thalassemia, as defined by foetal haemoglobin levels and clinical outcomes in patients with β-thalassemia? The significance of the result that modifying the BCL11A transcription factor will subsequently increase HbF is that it could be a vital component in improving current clinical outcomes in patients with β-thalassemia. The identified limitations of data collection that either support or refute the claim, as noted in the analysis, caused the formulation of a suggested improvement and extension to increase the reliability and validity of the experimental method in future investigations.
1 answer
1 answer